These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 21222497)

  • 101. Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients.
    Jezersek Novaković B; Benigar A
    Med Oncol; 2010 Jun; 27(2):167-76. PubMed ID: 19263255
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1S2):70-74. PubMed ID: 28140094
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
    Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Prolonging remission with rituximab maintenance therapy.
    Hainsworth JD
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Monoclonal antibodies in the treatment of cancer, Part 1.
    Cersosimo RJ
    Am J Health Syst Pharm; 2003 Aug; 60(15):1531-48. PubMed ID: 12951753
    [TBL] [Abstract][Full Text] [Related]  

  • 106. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.
    Belada D; Prochazka V; Janikova A; Campr V; Blahovcova P; Pytlik R; Sykorova A; Klener P; Benesova K; Pirnos J; Duras J; Mocikova H; Trneny M
    Leuk Res; 2018 Oct; 73():29-38. PubMed ID: 30195062
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Hill SL; Davies A
    Future Oncol; 2018 Jul; 14(17):1691-1699. PubMed ID: 29405071
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.
    Schulz H; Bohlius JF; Trelle S; Skoetz N; Reiser M; Kober T; Schwarzer G; Herold M; Dreyling M; Hallek M; Engert A
    J Natl Cancer Inst; 2007 May; 99(9):706-14. PubMed ID: 17470738
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera
    Shi Y; Zhang Q; Hong X; Wang Z; Gao Y; Zou L; Cen H; Gui L; Li Y; Feng J; Wang Z; Zhang M; Jin C; Zhang W; Hu J; Zheng C; Zheng Z; Zhang L; Chen S; Huang Y; Tang Y; Gao Y; Hao M; Li X; Chang C; Yang H; Wu H; Shen L; Ke X; Zhang L; Xi Y; Yang L; Xie L; Gai W; Ji Y
    Hematol Oncol; 2022 Dec; 40(5):930-940. PubMed ID: 35858181
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Rituximab as maintenance therapy for patients with follicular lymphoma.
    Vidal L; Gafter-Gvili A; Leibovici L; Shpilberg O
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006552. PubMed ID: 19370640
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews.
    Monga N; Garside J; Gurung B; Quigley J; O'Donovan P; Tapprich C; Nastoupil L; Thieblemont C; Loefgren C
    Pharmacoecon Open; 2020 Dec; 4(4):575-591. PubMed ID: 32200522
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Prolonging remission with rituximab maintenance therapy.
    Hainsworth JD
    Semin Oncol; 2004 Feb; 31 Suppl 2():17-21. PubMed ID: 28140104
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).
    Al-Kali A; Wierda W; Keating M; O'Brien S
    J Blood Med; 2010; 1():115-22. PubMed ID: 22282690
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
    Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg JW; Koff JL; Link BK; Cerhan JR; Dawson KL; Flowers CR
    Leuk Lymphoma; 2015 May; 56(5):1295-302. PubMed ID: 25263322
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
    Moccia AA; Zucca E; Ghielmini M
    Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
    J Natl Cancer Inst; 1999 May; 91(10):861-8. PubMed ID: 10340906
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.
    Adena M; Houltram J; Mulligan SP; Todd C; Malanos G
    Pharmacoeconomics; 2014 Feb; 32(2):193-207. PubMed ID: 24442832
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Ongoing trials in low-grade lymphoma.
    Burchardt A
    Hematol Rep; 2011 Oct; 3(3s):e5. PubMed ID: 22586513
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma.
    Fowler NH
    P T; 2011 Sep; 36(9):590-8. PubMed ID: 22346327
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Bendamustine in the treatment of non-Hodgkin's lymphomas.
    Hagemeister F; Manoukian G
    Onco Targets Ther; 2009 Feb; 2():269-79. PubMed ID: 20616914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.